Catalyst Event
Viatris Inc (VTRS) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/23/2026, 12:00:00 AM
Viatris announced on March 23, 2026, that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Effexor® SR capsules for the treatment of adults with generalized anxiety disorder (GAD), making it the first and only approved treatment for GAD in Japan.
Korean Translation
Viatris는 2026년 3월 23일, 일본 후생노동성(MHLW)이 성인 범불안장애(GAD) 치료를 위한 Effexor® SR 캡슐을 승인했다고 발표함. 이는 일본에서 GAD에 대해 승인된 최초이자 유일한 치료제가 됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM